Time to Discontinuation and Effectiveness of Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study

被引：0

作者：

Alten, R. ^{[1
]}

Burmester, G. ^{[2
]}

Matucci-Cerinic, M. ^{[3
,4
]}

Ostor, A. ^{[5
,6
]}

Zaremba-Pechmann, L. ^{[7
]}

Treuer, T. ^{[8
]}

Ng, K. ^{[8
]}

Gerwien, J. ^{[8
]}

Gibson, K. ^{[8
]}

Fautrel, B. ^{[9
,10
]}

机构：

[1] Univ Med Berlin, Dept Internal Med & Rheumatol, Schlosspk Klin, Berlin, Germany

[2] Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, Berlin, Germany

[3] Univ Florence, Div Rheumatol, Florence, Italy

[4] IRCCS San Raffaele Hosp, Unit Immunol Rheumatol Allergy & Rare Dis, Milan, Italy

[5] Monash Univ, Melbourne, Australia

[6] Emeritus Res, Camberwell, Australia

[7] HaaPACS GmbH, Schriesheim, Germany

[8] Eli Lilly & Co, Indianapolis, IN USA

[9] Sorbonne Univ, Pitie Salpetriere Hosp, Assistance Publ Hop Paris, Dept Rheumatol, Paris, France

[10] Pierre Louis Inst Epidemiol & Publ Hlth, PEPITES team, Paris, France

来源：

关键词：

Baricitinib; bDMARD; rheumatoid arthritis; tsDMARD;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PP02

引用

页码：60 / 61

页数：2